MicroRNA Expression in Circulating Microvesicles Predicts Cardiovascular Events in Patients With Coronary Artery Disease

被引:284
|
作者
Jansen, Felix [1 ]
Yang, Xiaoyan [4 ]
Proebsting, Sebastian [1 ]
Hoelscher, Marion [1 ]
Przybilla, David [1 ]
Baumann, Katharina [1 ]
Schmitz, Theresa [1 ]
Dolf, Andreas [2 ]
Endl, Elmar [2 ]
Franklin, Bernardo S. [3 ]
Sinning, Jan-Malte [1 ]
Vasa-Nicotera, Mariuca [1 ]
Nickenig, Georg [1 ]
Werner, Nikos [1 ]
机构
[1] Univ Bonn, Dept Internal Med 2, Bonn, Germany
[2] Univ Bonn, Inst Mol Med, Bonn, Germany
[3] Univ Bonn, Inst Innate Immun, Bonn, Germany
[4] Northwestern Univ, Sch Med, Feinberg Cardiovasc Res Inst, Chicago, IL USA
来源
关键词
coronary artery disease; microRNA; microvesicles; prognosis; ENDOTHELIAL MICROPARTICLES; VASCULAR INTEGRITY; DOWN-REGULATION; HEART-FAILURE; CELLS; ANGIOGENESIS; MIRNAS; INFLAMMATION; BIOMARKERS; MIR-126;
D O I
10.1161/JAHA.114.001249
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Circulating microRNAs (miRNAs) are differentially regulated and selectively packaged in microvesicles (MVs). We evaluated whether circulating vascular and endothelial miRNAs in patients with stable coronary artery disease have prognostic value for the occurrence of cardiovascular (CV) events. Methods and Results-Ten miRNAs involved in the regulation of vascular performance-miR-126, miR-222, miR-let7d, miR-21, miR-20a, miR-27a, miR-92a, miR-17, miR-130, and miR-199a-were quantified in plasma and circulating MVs by reverse transcription polymerase chain reaction in 181 patients with stable coronary artery disease. The median duration of follow-up for major adverse CV event-free survival was 6.1 years (range: 6.0-6.4 years). Events occurred in 55 patients (31.3%). There was no significant association between CV events and plasma level of the selected miRNAs. In contrast, increased expression of miR-126 and miR-199a in circulating MVs was significantly associated with a lower major adverse CV event rate. In univariate analysis, above-median levels of miR-126 in circulating MVs were predictors of major adverse CV event-free survival (hazard ratio: 0.485 [95% CI: 0.278 to 0.846]; P= 0.007) and percutaneous coronary interventions (hazard ratio: 0.458 [95% CI: 0.222 to 0.945]; P= 0.03). Likewise, an increased level of miR-199a in circulating MVs was associated with a reduced risk of major adverse CV events (hazard ratio: 0.518 [95% CI: 0.299 to 0.898]; P= 0.01) and revascularization (hazard ratio: 0.439 [95% CI: 0.232 to 0.832]; P= 0.01) in univariate analysis. miRNA expression analysis in plasma compartments revealed that miR-126 and miR-199a are present mainly in circulating MVs. MV-sorting experiments showed that endothelial cells and platelets were found to be the major cell sources of MVs containing miR-126 and miR-199a, respectively. Conclusion-MVs containing miR-126 and miR-199a but not freely circulating miRNA expression predict the occurrence of CV events in patients with stable coronary artery disease.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] LIVING IN SOCIALLY VULNERABLE NEIGHBORHOODS PREDICTS FUTURE CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ARTERY DISEASE
    Yadalam, Adithya
    Almuwaqqat, Zakaria
    Desai, Shivang
    Beydoun, Nour
    Alkhoder, Ayman
    Alras, Zahran
    Ko, Yi-An
    Lewis, Tene
    Kim, Jonathan H.
    Shah, Amit J.
    Sperling, Laurence S.
    Quyyumi, Arshed A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 987 - 987
  • [22] Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease
    Chirinos, J.
    Zambrano, J. P.
    Veerani, A.
    Schob, A.
    Perez, G.
    Mendez, A. J.
    Chakko, S.
    EUROPEAN HEART JOURNAL, 2005, 26 : 696 - 697
  • [23] Apolipoprotein E polymorphism predicts cardiovascular events in patients with stable multivessel coronary artery disease
    Lopes, N. H.
    Ferri, L. A. F.
    Lima, E. G.
    Vieira, R. D.
    Soares, P. R.
    Cesar, L. A.
    Hueb, W.
    Kriger, J. E.
    Pereira, A. C.
    Ramires, J. A. F.
    EUROPEAN HEART JOURNAL, 2009, 30 : 63 - 63
  • [24] Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease
    Chirinos, JA
    Zambrano, JP
    Chakko, S
    Veerani, A
    Schob, A
    Perez, G
    Mendez, AJ
    AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (05) : 11A - 12A
  • [25] Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease
    Chirinos, JA
    Zambrano, JP
    Chakko, S
    Veerani, A
    Schob, A
    Willens, HJ
    Perez, G
    Mendez, AJ
    HYPERTENSION, 2005, 45 (05) : 980 - 985
  • [26] Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study
    Katzmann, Julius L.
    Werner, Christian M.
    Stojakovic, Tatjana
    Maerz, Winfried
    Scharnagl, Hubert
    Laufs, Ulrich
    LIPIDS IN HEALTH AND DISEASE, 2020, 19 (01)
  • [27] Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study
    Julius L. Katzmann
    Christian M. Werner
    Tatjana Stojakovic
    Winfried März
    Hubert Scharnagl
    Ulrich Laufs
    Lipids in Health and Disease, 19
  • [28] Coronary artery calcification predicts cardiovascular events in patients on chronic hemodialysis patients
    Ohtake, Takayasu
    Oka, Machiko
    Hamasaki, Yoshifumi
    Maesato, Kyoko
    Mano, Tsutomu
    Ikee, Ryota
    Moriya, Hidekazu
    Kobayashi, Shuzo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 147 - 147
  • [29] Circulating microRNA expression profiling and bioinformatics analysis of dysregulated microRNAs of patients with coronary artery disease
    Zhong, Zhixiong
    Hou, Jingyuan
    Zhang, Qifeng
    Zhong, Wei
    Li, Bin
    Li, Cunren
    Liu, Zhidong
    Yang, Min
    Zhao, Pingsen
    MEDICINE, 2018, 97 (27)
  • [30] Circulating microRNA expression profiling and bioinformatics analysis of patients with coronary artery disease by RNA sequencing
    Zhong, Zhixiong
    Zhong, Wei
    Zhang, Qifeng
    Zhang, Qunji
    Yu, Zhikang
    Wu, Heming
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2020, 34 (01)